- Home
- DTF vs CALC Comparison
DTF vs CALC Comparison
Compare DTF & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTF | CALC |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.3M | 88.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DTF | CALC |
|---|---|---|
| Price | $11.47 | $0.68 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.1K | ★ 2.7M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.29 | $0.82 |
| 52 Week High | $11.19 | $7.20 |
Technical Indicators
Market Signals| Indicator | DTF | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 59.96 | 17.79 |
| Support Level | $11.41 | $0.82 |
| Resistance Level | $11.46 | $5.95 |
| Average True Range (ATR) | 0.05 | 0.45 |
| MACD | 0.00 | -0.61 |
| Stochastic Oscillator | 72.56 | 1.44 |
Price Performance
Historical ComparisonAbout DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.